A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Korábbi kezelés

• Participants with underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of investigational products hazardous
• Discontinued use of prior immune checkpoint therapy due to immune related adverse events; received prior treatment with an anti-TIGIT monoclonal antibody.
• History of trauma or major surgery within 28 days prior to enrollment.
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Egyéb

• Only for Cohort A: Known Human Epidermal Growth Factor Receptor 2 (HER-2) positive tumor
• Known untreated, symptomatic, or actively progressing central nervous system (brain) metastases. Participants with leptomeningeal metastases are excluded from enrollment.

• Participants with histologically confirmed diagnosis of locally advanced unresectable or metastatic gastric, GEJ, or esophageal adenocarcinoma with life expectancy ≥3 months as assessed by the Investigator
• Eastern cooperative oncology group (ECOG) Performance Score of 0-1
• At least one measurable target lesion per RECIST v1.1.
• Adequate organ and marrow function
• Able to provide an archival tumor sample that is representative of the cancer under investigation and suitable for central PD-L1 testing